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Summary
 Aim The aim of this works is the presentation of two cases of relapsed Ph positive acute lymphoblast-
ic leukaemia (ALL) to which the tyrosine inhibitor Imatinib (Glivec, Novartis) was applied. This 
therapy was earlier shown to be very helpful in the treatment of chronic myeloid leukemia.
 Case discription Case 1: A 17 year old patient with Ph positive T-ALL relapsed after allogenic transplantation of mar-
row and was treated with Imatinib in escalating doses from 200 to 600 mg per day. After 4 weeks 
of treatment the blastosis in the marrow had fallen from 96% to 7%. Blasts disappeared from the 
cerebrospinal ﬂ uid. At the same time, progression of hepatic and renal failure related to GVHD 
was observed. Imatinib withdrawal resulted in relapse, uncontrolled proliferation and the death 
of the patient.
 Results Case 2: Imatinib was used in the case of a 45 year old patient with Ph positive null-ALL and a me-
diastinal tumour. After autologous bone marrow transplantation, Imatinib therapy was begun for 
maintenance.. Daily doses of the drug amounted to only 200 mg owing to associated gastric com-
plaints. After two months of therapy, an increase in blast cells in the bone marrow to 18% was not-
ed. FLAM chemotherapy was given and complete haematological remission was achieved.
 Conclusions The cases described illustrate new possibilities in the treatment of Ph positive ALL. It is necessary, 
however, to conduct clinical trials in larger group of patients for the purposes of establishing opti-
mal dosing, the most suitable phase of the disease in which to begin therapy and possible combi-
nations with chemotherapy.
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BACKGROUND
The Philadelphia chromosome (Ph) is the most frequent-
ly identiﬁ ed genetic factor in adult patients with acute lym-
phoblastic leukaemia (ALL). The frequency with which the 
chromosome is identiﬁ ed in this group of patients is esti-
mated at between 20 and 40% [1]. Formation of the Ph 
chromosome is the result of a translocation between chro-
mosomes 9 and 22 {t(9;22)(q34; q11)} which leads to the 
formation of the oncogene BCR-ABL. Transcription of the 
oncogene in ALL produces an mRNA molecule, of mass 
7.5 kb, codes for a 190 kD protein (p-190). This process 
is the same as in chronic myeloid leukemia in which an 
mRNA molecule, of mass 8.5 kb, which codes for a 210 kD 
protein (p-210). The protein p-210 is the result of combin-
ing exons 2 of the ABL gene with exons 2 or 3 of the BCR 
gene (M-bcr region) (b2a2 and b3a2). Similarly p-190 re-
sults from the addition of exons 2 of the ABL gene to in-
tron 1 of the BCR gene (m-bcr region) (ela2). The GMALL 
study (German Multicenter Trials of Adult ALL) showed that 
77% of Ph positive ALL patients had the p-190 protein and 
20% had the p-210 protein. 3% were found to have both 
proteins [1]. Fused proteins have several domains, among 
the most important of which are those which show tyro-
sine kinase activity, involved in the inhibition of apoptosis 
and in the stimulation of tumour growth [2]. Ph positive 
ALL, almost exclusively, has immunological characteristics 
in common with pre-B [3]. In a signiﬁ cant number of cas-
es, leukaemia cells show expression of myeloid antigens. For 
example, within the LALA study group (Leucémie Aiguë 
Lymphoblastique de l’Adulte) CD34 was demonstrated in 
89%, CD13 in 20% and CD33 in 15% [4].
The prognosis for Ph positive ALL is decidedly poor; pa-
tients with this diagnosis are included in the very high risk 
(VHR) group. The frequency of complete remission (CR) 
in these groups reaches almost 70% compared to around 
85% in groups of Ph negative patients with ALL. Five year 
survival is less than 20% in comparison to around 48% in 
groups of patients with ‘standard’ risk. Survival time increas-
es by 30–35% after allogenic marrow transplantation in the 
ﬁ rst CR [1,3]. New treatment possibilities appeared for pa-
tients with Ph positive ALL with the introduction of imat-
inib (STI571, Glivec, Novartis). This drug is a tyrosine ki-
nase inhibitor and is unusually effective in cases of chronic 
myelogenous leukaemia (CML). It is possible to attain 95% 
complete haematological remission (CHR), 60% major cy-
togenetic response (MCR) and 41% complete cytogenetic 
remission (CCR) [5]. Further improvements in results can 
be attained by adding imatinib to chemotherapy, such as 
cytarabine [5]. The effectiveness of this drug in Ph positive 
ALL has not yet been fully described.
We present 2 cases of Ph positive ALL in which Imatinib 
was applied.
DESCRIPTION OF CASES
Case 1
A diagnosis of Ph positive pre-T cell ALL was made in the 
case of a 17 year old patient on the 26th of June, 2002. The 
results of additional tests are included in Table 1. The pa-
tient achieved CR thanks to application of EVAP therapy 
(epirubicin, vincristine, kidrolase, prednisone) according 
to the PALG (Polish Adult Leukemia Group) method. The 
course of treatment is illustrated in Table 2. Neurological 
symptoms arising during the period of remission consoli-
dating chemotherapy (n. VII paralysis, epilepsy) were, to be-
gin with, without change in the cerebrospinal ﬂ uid. Later, 
however, pleocytosis was observed (41/µl). Thanks to the 
application of cytostatic drugs and irradiation of the skull 
and spinal column, reversal of the neurological changes was 
achieved with normalization in the cerebrospinal ﬂ uid pic-
ture. On the 31st of December, 2002, an allogenic bone mar-
row transplantation was performed, the marrow having been 
obtained from a sister with suitable antigens. Unfortunately, 
on the 21st of March, 2003, recurrence of the disease was ob-
served. Apart from inﬁ ltrating leukaemic marrow and blood 
cells, changes found in the cerebrospinal ﬂ uid included ple-
ocytosis (350/µl). In the presence of increasingly serious 
symptoms of GVHD, (skin changes, diarhhoea, damage to 
the liver and kidneys) chemotherapy was halted and imat-
inib treatment was begun. The dose of the drug amount-
ed to between 200 and 600 mg and was dependent on the 
count of leucocytes and thrombocytes. Tests carried out af-
ter 4 weeks of treatment showed a reduction in the propor-
tion of blast cells in the marrow from 96% to 7% and, inter-
estingly, a normalisation in the morphological picture in the 
cerebro-spinal ﬂ uid. After 2 further weeks, the symptoms of 
liver damage (bilirubin 4.5 mg%) and kidney damage (cre-
atinine 4.2 mg%, urea 178 mg%) were so much more evi-
dent that it was decided to pause imatinib treatment. The 
break in treatment brought about uncontrolled prolifera-
tion during the following 2 weeks, culminating in the death 
of the patient on the 13th of May 2003.
Case 2
A 45 year old patient was diagnosed with Ph positive null-
cell ALL on the 8th of October, 2002. Additional test results 
and the course of treatment used are described in Tables 1 
and 2. On the 10th of November, following application of 
the EVAP scheme, CR was achieved. However, marrow tests 
performed after remission consolidating treatment showed 
an increase in the percentage of blast cells to 8%. FLAM 
treatment was applied (ﬂ udarabine, cytarabine, mitoxantro-
ne) and resulted in a return to complete remission. Owing 
to the lack of a source of marrow within the family for an 
allogenic transplant, it was decided to carry out and autol-
ogous transplant. After completing haemopoietic recon-
struction Imatinib treatment was begun. A small dose was 
used – 200 mg/day, owing to strong gastric disturbances 
(stomach pain, nausea, vomiting). After 2 months of treat-
ment, tests on the marrow showed an increase in the count 
of blast cells to 18%. It was decided that intensive FLAM 
therapy should be used, which again resulted in CR and, 
having identiﬁ ed a suitable non-related donor, the patient 
was admitted to the Marrow Transplantation Department 
in Wrocław where, unfortunately, the patient died follow-
ing a further replase in September 2003.
DISCUSSION
The presented cases illustrate new possibilities in the treat-
ment of Ph positive ALL. Imatinib, which is unusually ef-
fective in the treatment of CML, was very quickly applied to 
diseases characterised by this same type of genetic change. 
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The discovery of the great effectiveness of the drug was ﬁ rst 
shown in individual cases of resistant and relapsing Ph posi-
tive ALL [6–9], and later in a clinical trial on a larger group 
of patients. Ottmann et al. [10], working with a group of 
56 patients with resistant and relapsing Ph positive ALL, 
achieved CR in 29% of cases. The elementary loss of sensi-
tivity to imatinib and recurrence of disease is connected with 
resistance mechanisms such as: increased gene expression, 
ampliﬁ cation and point mutations, and also increased ex-
pression of multidrug resistance genes (MDR) [11]. An ef-
fective means of breaking the resistance of leukaemia cells 
is the combination of imatinib with chemotherapy. Thomas 
et al. [12] used the drug in association with a hyper-CVAD 
scheme on a group of 20 patients with newly diagnosed Ph 
positive ALL, achieving CR in all cases; 9 out of 10 patients 
who underwent further alloBMT attained a status of CR for 
an average 12 months, the other 10 patients in the group 
averaged 20 months in CR. Imatinib shows great value in 
the preparation of Ph positive ALL patients for alloBMT 
by bringing them to haematological and molecular remis-
sion, by elimination of residual BCR-ABL positive disease 
[13]. The obvious therapeutic possibilities of imatinib may 
give justiﬁ cation for autologous transplants in patients who 
have no alloBMT donors [14].
M, 17 years F, 45 years
Date of diagnosis 24-06-2002 08-11-2002
Type of Leukaemia pre-T
CD19- HLADR-
cCD3+(84%)TdT+(79%)
CD7+(83%)CD5(88%)
CD2 (95%) MDR-
null-cell
CD19-HLADR+(83%)
CD3-TdT+(22%)
CD34+(51%)CD13-CD33-
MDR-
Additional clinical details lymphadenopathy (till 2 cm) breast tumour
Blood morphology Hb 14.6 g% RBC 4.75 T/l
PLT 66 G/l WBC 132 G/l
blasts 75%
Hb 12.1g% RBC 3.59 T/l
PLT 195 G/l WBC 145 G/l
blasts 70%
Myelogram 89% cells with morphology
of small lymphoblasts
90% cells with morphology
of small lymphoblasts
Genetic fi ndings BCR/ABL + (30% cells, FISH) BCR/ABL+ (22% cells, FISH)
Table 1. Description of patients with Ph positive ALL, treated with imatinib: Clinical picture at the time of diagnosis.
M, 17 years F, 45 years
Treatment type (commencement date) EVAP according to PALG
(26-06-2002)
EVAP according to PALG
(08-11-2002)
Result of treatment (date) CR (13-08-2002) CR (10-12-2002)
Post-remission
treatment
Consolidation (PALG)
Treatment of meningeal leukaemia, which appeared 
in the consolidation phase, fi rst with neurological 
symptoms (n. VII paralysis, epilepsy), and later, 
changes in the cerebrospinal fl uid – irradiation, 
cytostatics
AlloBMT (31-12-2002)
Relapse: 21-03-2003
IMATINIB
- 6 week treatment with doses between 200 and 
600 mg; after 4 weeks there was a reduction in 
blasts in the marrow from 96% to 7% and in the 
CSF from 350 to 3/ul
- treatment halted owing to liver and kidney 
damage (GVHD)
Death: 13.05.2003
Consolidation (PALG)
8% blasts in marrow – FLAM
AutoPBPCT (01-04-2003)
IMATINIB
– 2 month treatment with doses between 200 
and 400 mg (owing to stomach pain, nausea, 
vomiting)
Relapse (blasts 18%)
FLAM
Death: 09.2003 
Table 2. Patients with Ph positive ALL: course of treatment.
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The cases we present are very interesting from the point of 
view of casuistry of the Philadelphia chromosome in pre-T 
and null cell ALL. In the ﬁ rst patient, imatinib was used in 
early relapse after alloBMT, together with CUN, and strong 
symptoms of GVHD led to an accumulation of toxic symp-
toms. Nevertheless, a reduction in the count of blast cells 
in the marrow was seen, from 96% to 7% and, interesting-
ly, in the cerebrospinal ﬂ uid from 350 to 3 in 1 µl. In the 
second case an attempt was made to eliminate residual dis-
ease after autologous transplantation of marrow cells. One 
of the causes for the lack of response was the use of a re-
duced dosage of the drug (200 mg), because of gastric dis-
tress, which has been reported in the majority of patients 
(70%) during imatinib treatment [3]. Complete remission 
was achieved after chemotherapy.
In our opinion imatinib is of the highest value in the treatment 
of Ph positive ALL when combined with chemotherapy and 
in the preparation of patients for transplantation of marrow, 
probably including autologous transplantation. The ﬁ xing of 
optimal dosing, in relation to the composition of chemother-
apy and phases of disease in which the drug should be used, 
demands clinical trials in a larger group of patients.
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